The U.S. Food and Drug Administration placed a clinical hold on Tryp Therapeutics’ Phase IIa trial for eating disorders, including binge eating disorder and hypothalamic obesity.

A rare fungus that can cause drug-resistant infections has been found in around 200 patients in more than 55 hospitals across Britain, health officials said.